REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

14/10/2020 15:30

RNS Number : 1062C
  
GlaxoSmithKline PLC
  
14 October 2020
  
 

GlaxoSmithKline plc (the 'Company')
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


891


 




 


£14.2540


887


 




 


£14.2540


714


 




 


 


 


 




d)


Aggregated information
 


2,492




 
Aggregated volume Price


 
£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr H Barron




b)


Position/status


Chief Scientific Officer and President, R&D




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 October 2020 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$37.1600


521


 




 


$37.1600


409


 




 


 


 


 




d)


Aggregated information
 


930




 
Aggregated volume Price


 
$37.1600




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor     
 




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


225


 




 


£14.2540


232


 




 


£14.2540


188


 




 


 


 


 




d)


Aggregated information
 


645




 
Aggregated volume Price


 
£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


92


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


132


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 October 2020 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$37.1600


44


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


99


 




 


£14.2540


97


 




 


£14.2540


70


 




 


 


 


 




d)


Aggregated information
 


266




 
Aggregated volume Price


 
£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


56


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I Mackay




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


482


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 October 2020 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$37.1600


87


 




 


$37.1600


93


 




 


$37.1600


75


 




 


 


 


 




 


 


 


 




d)


Aggregated information
 


255




 
Aggregated volume Price


 
$37.1600




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


179


 




 


£14.2540


216


 




 


£14.2540


247


 




 


 


 


 




d)


Aggregated information
 


642




 
Aggregated volume Price


 
£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


183


 




 


£14.2540


220


 




 


£14.2540


158


 




 


 


 


 




d)


Aggregated information
 


561




 
Aggregated volume Price


 
£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


79


 




 


£14.2540


112


 




 


 


 


 




d)


Aggregated information
 


191




 
Aggregated volume Price


 
£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 October 2020 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$37.1600


31


 




 


$37.1600


110


 




 


$37.1600


76


 




 


 


 


 




d)


Aggregated information
 


217




 
Aggregated volume Price


 
$37.1600




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2540


124


 




 


£14.2540


128


 




 


£14.2540


91


 




 


 


 


 




d)


Aggregated information
 
 


343




Aggregated volume Price


£14.2540




e)


Date of the transaction


2020-10-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHZZLFFBBLLFBE